索拉非尼治疗晚期肝细胞性肝癌耐受性研究.docVIP

生堡塞坠处整盘查垫!Q生!Q旦筮22鲞筮!Q塑垦堑!』曼望!坚望:Q!鲤蛙!垫!Q:!尘:!!:丛!:!Q ?1535临床研究? 索拉非尼治疗晚期肝细胞性肝癌的耐受性 研究 王俐稔钱建民汪防睿王乾伟 马震宇 【摘要】 目的探讨索拉非尼在临床治疗晚期原发性肝癌中的耐受性、安全性及相关疗效。 方法对2008年11月至2009年11月间于我院诊断晚期原发性肝癌接受索拉非尼治疗的患者的 相关临床数据进行分析,应用t检验及,检验。结果本研究16例患者,平均生存时间12.37个 月。治疗前Child评分A级者11例、B级3例、C级2例;治疗3个月后,治疔前A级患者中4例进 展至B级,B级中2例进展至c级。治疗前MELD平均值为5.3l,治疗后1个月为5.38(P0.05), 治疗后3个月为6.67(PO.05)。治疗前Child A级的患者平均总生存期为14.00个月,B/C级患 者为8.80个月(P0.05)。根据BCLC分期,B级患者的平均生存时间为13.70个月,C/D级患者 的平均生存时间为10.17个月。结论索拉非尼治疗可延长晚期肝细胞性肝癌的总生存期,并且在 不同肝功能状态的患者中均耐受性良好。 【关键词】索拉非尼;癌,肝细胞 Tolersn∞of sorafenib in the treatment of advanced hepatocellular carcinoma形tJ7、『G Li.reB. QIAN Jian-min,WANG Fang一枷,砺lⅣG Qian?wei,MA Zhen?yu.Department of General Surgery,Huashan Hospital,Fudan University,Shanghai 2DD倒0,China 【Abstract】 Objective To evaluate tlle tolerance。safety and curative effect of sorafenib in the treatment of advanced hepatocellular carcinoma(HCC).Methods The clinical data of 16 cases of pa- tients who had been diagnosed as unresectable HCC from November 2008 to November 2009 were retrospee. tively analyzed.Results The average survival time was 12.37 months.W1len stratified according to Child?Push score,there were 11,3 and 2 patients in grades A,B,C respectively before the therapy.One month later.one patient of grade A WaS transformed to B。and one of grade B to C.Three months later。4 patients of grade A was transformed to B.and 2 of grade B to C.The average model for end?stage liver dis- PAtSe(MELD)score beforethetherapywas 5.3l,andthatwas 5.38(P0.05)onemonthlater and 6.67 (P0.05)three months later.The average survival time of Child A and Child B/C was 14.00 and 8.80 months respectively(P0.05).If stratified according to BCLC grade,the average survival time in grade B group and grade c/D group Was 13.70 and 9.50 months respectively.Conclusion Sorafenib may pro- long tlle total survival time of patients with advanced HCC,and it was well tolerated in patients with differ- ent states of liver function. 【Key words】 Sorafenib; Carcinoma,